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Cytokines have pivotal roles in the maintenance of an
appropriate immune response. Targeting cytokine
receptors has been an effective means of treating
immune-related disorders. In the past few years,
research efforts have been directed toward cytokines’
intracellular signaling pathways and, in particular, the
JAK-STAT (Janus kinase-signal transducers and activa-
tion of transcription) signaling cascade. Recently,
spearheaded by the development of effective drugs
in cancer treatment, it has become clear that the
targeting of intracellular protein kinases is a very
attractive and feasible possibility for the treatment of
autoimmune disorders. The targeting of the Janus
kinases (JAKs) has been quite successful and two JAK
inhibitors are now approved to be used in humans.
Interestingly, although some of the inhibitors devel-
oped and tested to date have been shown to target
more than one kinase, this promiscuity does not
appear to be problematic. Novel second-generation,
more specific inhibitors are under development, and
in the next few years, we expect this class of drugs to
become a powerful tool in the hands of clinician
treating autoimmune diseases.
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Cytokines are soluble factors with critical functions in several
biological responses. In particular, they serve as an intracel-
lular communication tool of immune system, and their release
and actions help shape the immune response. As a result,
when these molecules are produced in abnormal amounts, be
these higher or lower, the homeostasis of the immune system
is altered and several pathologies ensue (O’Shea et al., 2011).
Autoimmune disorders are a classical example of such
pathologies as several proinflammatory cytokines have been
demonstrated to drive such diseases (Xavier and Rioux, 2008).
It was not surprising then that targeting cytokines and their
receptors resulted in the development of several drugs
currently utilized to treat autoimmune diseases. The class of
drugs known as biologics, which includes mAbs, recombinant
soluble receptors, and fusion proteins of receptor moieties
with antibodies’ constant fragments, has, in the past 15 years,
completely revolutionized the clinical approach to the
treatment of immune disorders (Strand et al., 2007).
Like any other drugs, biologics are not magic bullets and
their use has some limitations. First of all, these drugs have to
be administered parenterally. Moreover, being proteins in
nature, they often have high molecular weight and therefore
do not cross the blood–brain barrier and cannot function
within the central nervous system. Importantly, some patients
are refractory to their effects and the high cost is an issue in
some countries.
Like many soluble factors, cytokines bind to their receptors
on the surface of cells and trigger signaling events that involve
several cytosolic substrates. These substrates would be ideal
targets for the development of small molecules aiming at
modulating cellular responses. On the other hand, because of
the complexity and the intricacies of signaling pathways, the
goal is not easily achievable.
In the case of cytokines, the activation of the tyrosine kinase
of the Janus family, better known as JAKs, were shown to be a
critical step. This family comprises four molecules, namely
JAK1, JAK2, JAK3, and TYK2. Upon binding of cytokines to
their cognate receptors, JAKs, which work in pairs, become
enzymatically active and phosphorylate themselves, the
receptor chains, and several other substrates including the
signal transducers and activation of transcription family of
latent transcription factors (Leonard and O’Shea, 1998)
(Figure 1).
Cytokines act on different cells, and likewise, JAKs are
expressed in many cell types. On the other hand, JAK3 is
selectively expressed in hematopoietic cells and mutation in
this kinase resulted in loss of function and severe-combined
immunodeficiency in humans (Leonard and O’Shea, 1998).
It was therefore hypothesized that blocking the enzymatic
activity of JAK3 would also result in immunosuppression.
Importantly, mutations in JAK2 have also been reported in
humans but this resulted in a gain of function as cells
expressing the mutant JAK2 proliferate in a cytokine-
independent manner (Kralovics et al., 2005).
Small molecules such as imatinib, which blocked the
ATP-binding activity of tyrosine kinases, were successfully
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generated and have been used in the treatment of several
malignancies including leukemia, lymphomas, and even
some solid tumors. Therefore, development of specific JAK
inhibitors was not only desirable but also feasible.
Twenty years after the discovery of the JAKs and the definition
of their role in cytokine signaling, this has now become
a reality.
Recently, two small molecules that inhibit JAKs’ enzymatic
activity have been approved for clinical use. Ruxolitinib (trade
name Jakafi) is a JAK2/JAK1 inhibitor (with some activity on
JAK3 and TYK2) currently prescribed for the treatment of
intermediate- or high-risk myeloproliferative disorders includ-
ing primary myelofibrosis post-polycythemia vera myelo-
fibrosis and post-essential thrombocythemia myelofibrosis
(Harrison et al., 2012).
Tofacitinib (trade name Xeljianz) instead is a JAK3/JAK1
inhibitor (but JAK2 is also affected, albeit to a lesser extent)
recently approved for the treatment of rheumatoid arthritis in
patients for whom methotrexate therapy was not efficacious.
In these cases, tofacitinib is used either as monotherapy or it
can be combined with methotrexate or other non-biologic
disease-modifying antirheumatic drugs (Fleischmann et al.,
2012; van Vollenhoven et al., 2012).
Both these first-generation JAK inhibitors block the enzy-
matic activity of all the JAKs with different degrees of
specificity. In vitro studies have shown that, with regard to
the human kinome, their activity is exquisitely limited to the
JAKs (Karaman et al., 2008). This specificity limits their off-
target effects but does not impair their capacity to blunt the
effects of multiple cytokines. In fact, in the case of tofacitinib,
the capacity to inhibit the actions of several proinflammatory
cytokines and to act on different immune cells is possibly out
of the reasons why this drug has been so efficacious in
rheumatoid arthritis, a disease that pathophysiology involves
the action of several cytokines.
Blocking cytokines such as interleukins, interferons, and
erythropoietin results in effects on many cell types such as T,
B, natural killer cells, and erythrocytes. Administration of a
JAK2 inhibitor like ruxolitinib results in anemia and thrombo-
cytopenia, as expected by the well-known role of JAK2 in
erythropoietin and thrombopoietin signal transduction. On the
other hand, patients receiving the drug showed clinical improve-
ment in all the myelofibrosis-related symptoms (Mascarenhas
and Hoffman, 2012).
In the case of tofacitinib, the total number of circulating T
cells is not impaired but differentiation of T helper cells such
as T helper type 1, T helper type 2, and T helper type 17 is
impaired (Ghoreschi et al., 2011). Animal studies have
also shown a sharp decline in numbers of natural killer
cells. Patients treated with tofactinib tended to be more
prone to infections, which included opportunistic pathogens
and herpes zoster. The above-mentioned effect on natural
killer cells does not appear to correlate with increased
incidence of tumors but long-term effects have not yet been
evaluated.
Overall, JAK inhibitors’ side effects partially overlap with
what has been observed for biologics. Increased lipids levels,
observed in patients receiving JAK inhibitors, have also been
reported in patients treated with the anti-IL-6 antibody
tocilizumab. Similarly, increased creatinine and transaminase
levels were detected but it remains unclear if such alterations
or the increase in lipids are directly related to JAK enzymatic
activity.
Several clinical trials with other JAK inhibitors are currently
ongoing for a wide array of diseases ranging from immune-
mediated diseases, such as psoriasis, and inflammatory bowel
disease to malignancies like myeloid leukemias and multiple
myeloma. JAK inhibitors are also being tested as immunosup-
pressants in transplantation.
Some of the new, ‘‘second-generation’’ inhibitors appear to
be more specific. For example, GLPG0634, currently devel-
oped by Galapagos has been reported to be JAK1-specific,
whereas Vertex’s VX-509 is JAK3-selective. However, it is not
known whether this selectivity will result in increased efficacy.
Nonetheless, we are tempted to speculate that these com-
pounds may be better suited for diseases in which only one or
very few cytokines are implicated. The mechanism of delivery
(e.g. orally, parenterally, or topically) also needs to be
considered with regard to their use.
In conclusion, targeting of JAKs was pursued because of
their expression pattern and association with several pathol-
ogies. We can now say that inhibition of JAK enzymatic
activity has clearly proved successful for some immune-
related diseases, whereas other immune-related pathologies
will likely soon benefit from this class of drugs.
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Figure 1. Janus kinase (JAK) inhibitors block JAKs enzymatic activity
activation. Cytokines or interferons bind their cognate receptors and initiate a
signaling cascade leading to the activation of the latent transcription factors
signal transducers and activation of transcription factors (STAT) and ultimately
gene transcription. JAK inhibitors interfere with this pathway by blocking JAKs’
enzymatic activity.
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